Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Announces Earnings Results

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) released its earnings results on Tuesday. The company reported $0.18 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.03, Zacks reports. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 41.82% and a return on equity of 13.70%.

Shionogi & Co., Ltd. Unsponsored ADR Trading Down 14.7%

Shares of SGIOY stock traded down $1.50 during trading on Tuesday, hitting $8.67. 520,844 shares of the stock traded hands, compared to its average volume of 101,658. The firm has a market capitalization of $14.76 billion, a P/E ratio of 11.41, a price-to-earnings-growth ratio of 0.75 and a beta of 0.10. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.84 and a quick ratio of 5.21. The firm’s fifty day moving average price is $10.57 and its 200-day moving average price is $9.77. Shionogi & Co., Ltd. Unsponsored ADR has a 52-week low of $7.38 and a 52-week high of $12.00.

Wall Street Analyst Weigh In

SGIOY has been the topic of a number of research reports. Zacks Research lowered shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong sell” rating in a research note on Thursday, April 16th. The Goldman Sachs Group raised shares of Shionogi & Co., Ltd. Unsponsored ADR to a “hold” rating in a research note on Wednesday, April 8th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Shionogi & Co., Ltd. Unsponsored ADR currently has a consensus rating of “Reduce”.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.